REZDIFFRA (resmetirom) – MASH, formerly NASH Therapy in India
Rezdiffra (resmetirom) is the first FDA-approved medication for adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) who have moderate to advanced liver scarring (fibrosis), used alongside diet and exercise to reduce liver fat, inflammation, and scarring by targeting liver thyroid hormone receptors. It’s an oral tablet taken once daily and works as a liver-directed therapy, though potential side effects include diarrhea, nausea, itching, and gallbladder issues, with ongoing studies confirming its long-term benefits.
| Brand Name: | REZDIFFRA |
| Generic Name: | Resmetirom Tablets |
| Strength: | • Tablets: 60 mg, 80 mg, and 100 mg |
| Manufacturer: | Madrigal Pharmaceuticals |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
REZDIFFRA must always be used under the supervision of a Registered Medical Practitioner (RMP).
Access REZDIFFRA for MASH, formerly NASH on a Named Patient Import Basis
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to REZDIFFRA (resmetirom) tablets for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.
